Olivier Tournilhac

Clermont-ferrand, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 167 publications

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal: Journal of hematology & oncology
Published: March 15, 2026

Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.

Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.

Journal: Blood advances
Published: February 19, 2026

Prognostic value of combined baseline FDG PET/CT radiomic parameters in primary mediastinal B-cell lymphoma.

Prognostic value of combined baseline FDG PET/CT radiomic parameters in primary mediastinal B-cell lymphoma.

Journal: Blood advances
Published: February 19, 2026

Genomic loss of MLH1/PMS2 loci defines a mismatch repair deficient subgroup in monomorphic epitheliotropic intestinal T-cell lymphoma.

Genomic loss of MLH1/PMS2 loci defines a mismatch repair deficient subgroup in monomorphic epitheliotropic intestinal T-cell lymphoma.

Journal: Blood cancer journal
Published: January 23, 2026

Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.

Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.

Journal: Leukemia
Published: November 20, 2025

Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party.

Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party.

Journal: HemaSphere
Published: October 02, 2025

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Journal: Blood advances
Published: September 17, 2025

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Journal: EClinicalMedicine
Published: July 30, 2025

Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.

Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.

Journal: Leukemia
Published: July 28, 2025

Imatinib-Induced Reactive Angioendotheliomatosis: A Paradoxical Pro-Angiogenic Case.

Imatinib-Induced Reactive Angioendotheliomatosis: A Paradoxical Pro-Angiogenic Case.

Journal: International journal of dermatology
Published: July 11, 2025

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)
Published: June 28, 2025

Chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia

Journal: La Revue du praticien
Published: June 23, 2025
Showing 1-12 of 167

Last Updated: 09/26/2026